Insuficiencia cardiaca con fracción de eyección conservada: ¿Cómo podemos abordarla?
Palabras clave:
Insuficiencia Cardíaca, Fracción de eyección, Biomarcadores, Fenotipo, Tratamiento
Resumen
Resumen
La insuficiencia cardiaca con fracción de eyección preservada (ICFEp) constituye un síndrome con una prevalencia de 1 - 5.5 % que se asocia a edad avanzada y para el cual se han identificado diversos mecanismos inflamatorios y metabólicos que desencadenan las alteraciones estructurales que la caracterizan y a su vez resultan en signos y síntomas característicos. Para su diagnóstico se deben reunir características clínicas con el estudio ecocardiogragico, y pese a su implicación en la mortalidad de los individuos afectados, en la actualidad no se dispone de medidas efectivas para disminuir adversos por lo que se suele dar manejo a cada comorbilidad, e incluso se ha postulado orientar la terapia hacia subgrupos con características definidas. Para la presente revisión de tema se realizó una revisión bibliográfica de diferentes bases de datos priorizando información obtenida en estudios aleatorizados y meta-análisis
Descargas
Los datos de descargas todavía no están disponibles.
Disciplinas:
Medicina Interna, CardiologíaReferencias bibliográficas
1. Redfield M. Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine. 2016;375(19):1868-1877.
2. Ponikowski P, Voors A, Anker S, Bueno H, Cleland J, Coats A et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure. 2016;18(8):891-975.
3. Oktay A, Shah S. Diagnosis and Management of Heart Failure with Preserved Ejection Fraction: 10 Key Lessons. Current Cardiology Reviews. 2014;11(1):42-52.
4. Oktay A, Rich J, Shah S. The Emerging Epidemic of Heart Failure with Preserved Ejection Fraction. Current Heart Failure Reports. 2013;10(4):401-410.
5. Gómez E. Identificación de pacientes con falla cardiaca y función sistólica preservada: Un estudio epidemiológico regional (I-PREFER Study) – Colombia. Revista Colombiana de Cardiología. 2013;20(2):58-67.
6. Tibrewala A, Yancy C. Heart Failure with Preserved Ejection Fraction in Women. Heart Failure Clinics. 2019;15(1):9-18.
7. Tromp J, MacDonald M, Tay W, Teng T, Hung C, Narasimhan C et al. Heart Failure With Preserved Ejection Fraction in the Young. Circulation. 2018;138(24):2763-2773.
8. Gupta D, Shah A, Castagno D, Takeuchi M, Loehr L, Fox E et al. Heart Failure With Preserved Ejection Fraction in African Americans. JACC: Heart Failure. 2013;1(2):156-163.
9. Lai Y, Wang L, Gladwin M. Insights into the Pulmonary Vascular complications of heart failure with Preserved Ejection Fraction. The Journal of Physiology. 2018;.
10. Borlaug B. The pathophysiology of heart failure with preserved ejection fraction. Nature Reviews Cardiology. 2014;11(9):507-515.
11. Cikes M, Claggett B, Shah A, Desai A, Lewis E, Shah S et al. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure. 2018;6(8):689-697.
12. Vaduganathan M, Patel R, Michel A, Shah S, Senni M, Gheorghiade M et al. Mode of Death in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology. 2017;69(5):556-569.
13. Zile M, Litwin S. Heart Failure with a Preserved Ejection Fraction. En: Zipes D, Libby P, Bonow R, Mann D, Tomaselli G. Editors. Braunwald heart disease a textbooks of cardiovascular medicine. Eleventh edition. Philadelphia: ELSEVIER; 2019. P. 1287-1344
14. Lam C, Voors A, de Boer R, Solomon S, van Veldhuisen D. Heart failure with preserved ejection fraction: from mechanisms to therapies. European Heart Journal. 2018;39(30):2780-2792.
15. Meijers W, van der Velde A, de Boer R. Biomarkers in heart failure with preserved ejection fraction. Netherlands Heart Journal. 2016;24(4):252-258.
16. Iwano H, Little W. Heart failure: What does ejection fraction have to do with it?. Journal of Cardiology. 2013;62(1):1-3.
17. Mentz R, Kelly J, von Lueder T, Voors A, Lam C, Cowie M et al. Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction. Journal of the American College of Cardiology. 2014;64(21):2281-2293.
18. Hegde S, Claggett B, Shah A, Lewis E, Anand I, Shah S et al. Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist). Circulation. 2017;136(11):982-992.
19. Pandey A, Parashar A, Kumbhani D, Agarwal S, Garg J, Kitzman D et al. Exercise Training in Patients With Heart Failure and Preserved Ejection Fraction. Circulation: Heart Failure. 2015;8(1):33-40.
20. Shah S, Kitzman D, Borlaug B, van Heerebeek L, Zile M, Kass D et al. Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction. Circulation. 2016;134(1):73-90.
21. Pandey A, Patel K, Vaduganathan M, Sarma S, Haykowsky M, Berry J et al. Physical Activity, Fitness, and Obesity in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure. 2018;6(12):975-982.
22. Yancy C, Jessup M, Bozkurt B, Butler J, Casey D, Drazner M et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation. 2013;128(16).
23. de Denus S, O’Meara E, Desai A, Claggett B, Lewis E, Leclair G et al. Spironolactone Metabolites in TOPCAT — New Insights into Regional Variation. New England Journal of Medicine. 2017;376(17):1690-1692.
24. Zheng S, Chan F, Nabeebaccus A, Shah A, McDonagh T, Okonko D et al. Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart. 2017;104(5):407-415.
25. Martin N, Manoharan K, Thomas J, Davies C, Lumbers R. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database of Systematic Reviews. 2018;.
26. Bavishi C, Chatterjee S, Ather S, Patel D, Messerli F. Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis. Heart Failure Reviews. 2014;20(2):193-201.
27. Solomon Scott, Mc Murray John, E et al. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction- PARAGON HF The NEJM 2019 ; September 1: Pag1-11.
28. Sueta Daisuki, Yamamoto Eiichiro, et al. H2FPEF Score as a Prognostic Value in HFpEF patients. American Journal of Hypertension, 2019: Pag 1-37
2. Ponikowski P, Voors A, Anker S, Bueno H, Cleland J, Coats A et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure. 2016;18(8):891-975.
3. Oktay A, Shah S. Diagnosis and Management of Heart Failure with Preserved Ejection Fraction: 10 Key Lessons. Current Cardiology Reviews. 2014;11(1):42-52.
4. Oktay A, Rich J, Shah S. The Emerging Epidemic of Heart Failure with Preserved Ejection Fraction. Current Heart Failure Reports. 2013;10(4):401-410.
5. Gómez E. Identificación de pacientes con falla cardiaca y función sistólica preservada: Un estudio epidemiológico regional (I-PREFER Study) – Colombia. Revista Colombiana de Cardiología. 2013;20(2):58-67.
6. Tibrewala A, Yancy C. Heart Failure with Preserved Ejection Fraction in Women. Heart Failure Clinics. 2019;15(1):9-18.
7. Tromp J, MacDonald M, Tay W, Teng T, Hung C, Narasimhan C et al. Heart Failure With Preserved Ejection Fraction in the Young. Circulation. 2018;138(24):2763-2773.
8. Gupta D, Shah A, Castagno D, Takeuchi M, Loehr L, Fox E et al. Heart Failure With Preserved Ejection Fraction in African Americans. JACC: Heart Failure. 2013;1(2):156-163.
9. Lai Y, Wang L, Gladwin M. Insights into the Pulmonary Vascular complications of heart failure with Preserved Ejection Fraction. The Journal of Physiology. 2018;.
10. Borlaug B. The pathophysiology of heart failure with preserved ejection fraction. Nature Reviews Cardiology. 2014;11(9):507-515.
11. Cikes M, Claggett B, Shah A, Desai A, Lewis E, Shah S et al. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure. 2018;6(8):689-697.
12. Vaduganathan M, Patel R, Michel A, Shah S, Senni M, Gheorghiade M et al. Mode of Death in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology. 2017;69(5):556-569.
13. Zile M, Litwin S. Heart Failure with a Preserved Ejection Fraction. En: Zipes D, Libby P, Bonow R, Mann D, Tomaselli G. Editors. Braunwald heart disease a textbooks of cardiovascular medicine. Eleventh edition. Philadelphia: ELSEVIER; 2019. P. 1287-1344
14. Lam C, Voors A, de Boer R, Solomon S, van Veldhuisen D. Heart failure with preserved ejection fraction: from mechanisms to therapies. European Heart Journal. 2018;39(30):2780-2792.
15. Meijers W, van der Velde A, de Boer R. Biomarkers in heart failure with preserved ejection fraction. Netherlands Heart Journal. 2016;24(4):252-258.
16. Iwano H, Little W. Heart failure: What does ejection fraction have to do with it?. Journal of Cardiology. 2013;62(1):1-3.
17. Mentz R, Kelly J, von Lueder T, Voors A, Lam C, Cowie M et al. Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction. Journal of the American College of Cardiology. 2014;64(21):2281-2293.
18. Hegde S, Claggett B, Shah A, Lewis E, Anand I, Shah S et al. Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist). Circulation. 2017;136(11):982-992.
19. Pandey A, Parashar A, Kumbhani D, Agarwal S, Garg J, Kitzman D et al. Exercise Training in Patients With Heart Failure and Preserved Ejection Fraction. Circulation: Heart Failure. 2015;8(1):33-40.
20. Shah S, Kitzman D, Borlaug B, van Heerebeek L, Zile M, Kass D et al. Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction. Circulation. 2016;134(1):73-90.
21. Pandey A, Patel K, Vaduganathan M, Sarma S, Haykowsky M, Berry J et al. Physical Activity, Fitness, and Obesity in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure. 2018;6(12):975-982.
22. Yancy C, Jessup M, Bozkurt B, Butler J, Casey D, Drazner M et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation. 2013;128(16).
23. de Denus S, O’Meara E, Desai A, Claggett B, Lewis E, Leclair G et al. Spironolactone Metabolites in TOPCAT — New Insights into Regional Variation. New England Journal of Medicine. 2017;376(17):1690-1692.
24. Zheng S, Chan F, Nabeebaccus A, Shah A, McDonagh T, Okonko D et al. Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart. 2017;104(5):407-415.
25. Martin N, Manoharan K, Thomas J, Davies C, Lumbers R. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database of Systematic Reviews. 2018;.
26. Bavishi C, Chatterjee S, Ather S, Patel D, Messerli F. Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis. Heart Failure Reviews. 2014;20(2):193-201.
27. Solomon Scott, Mc Murray John, E et al. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction- PARAGON HF The NEJM 2019 ; September 1: Pag1-11.
28. Sueta Daisuki, Yamamoto Eiichiro, et al. H2FPEF Score as a Prognostic Value in HFpEF patients. American Journal of Hypertension, 2019: Pag 1-37
Cómo citar
(1)
Orozco-Burbano, J. D.; Cabrera-Velasco, C. E.; Ortiz-Andrade, J. I.; López-Garzón, N. A. Insuficiencia Cardiaca Con fracción De eyección Conservada: ¿Cómo Podemos Abordarla? . Rev. Fac. Cienc. Salud Univ. Cauca 2020, 22, 26-33.
Publicado
2020-07-01
Sección
Artículos de revisión
.png)
